

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.

Drug Requested: Vyvanse® (lisdexamfetamine) for BINGE EATING DISORDER (BED)

DRUG INFORMATION: Complete information below. Authorization process will be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Recommended dose is 30 mg/day. **Maximum dose is 70mg/day.**

CLINICAL CRITERIA: Check below ALL that apply. Boxes must be checked to qualify or authorization process will be delayed. Chart notes (documentation) **MUST** be attached to request.

Initial Authorization
6 month time period

| | | |
|---|---|-----------------------------|
| Patient eats in a set amount of time an amount of food that is definitely larger than what most people would eat in that same amount of time. | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Patient has a sense of lack of control over eating. | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Patient's binge eating episodes are associated with <u>3 OR MORE</u> of the following: <ul style="list-style-type: none"> <input type="checkbox"/> Eating much more rapidly than normal <input type="checkbox"/> Eating until feeling uncomfortably full <input type="checkbox"/> Eating large amounts of food when not feeling physically hungry <input type="checkbox"/> Eating alone because of embarrassment over how much one is eating <input type="checkbox"/> Feeling disgusted, guilty, or depressed afterward | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Patient has marked distress regarding the presence of binge eating | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Patient's binge eating occurs, on average, at least once a week for 3 months | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Patient's binge eating is associated with the use of inappropriate compensatory mechanisms | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Patient is diagnosed with bulimia nervosa or anorexia nervosa | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Please provide member's height, weight, and BMI: | Ht: _____ Wt: _____ BMI: _____ | |
| Please provide the number of binge eating days/week that member experiences: | # of Binge Eating Days/Week: _____ | |
| Patient is currently receiving psychotherapy from a behavioral health clinician | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| **CHART NOTES DOCUMENTING THAT THE MEMBER MEETS <u>ALL DSM CRITERIA</u> AND IS <u>RECEIVING PSYCHOTHERAPY</u> MUST BE SUBMITTED FOR APPROVAL** | <input type="checkbox"/> Chart Notes Attached | |

****Length of Initial Authorization is 6 MONTHS; Continued Approval is based on submission of progress notes documenting improvement (decrease in binge eating Days/Week and weight.)****

(continued on next page)

Continued Approval
*based on submission of Progress notes documenting improvement
(decrease in Binge Eating days/week and weight)*

| | | | |
|--|---|--|---|
| <input type="checkbox"/> Date: _____ | <input type="checkbox"/> # of Binge Eating Days/Week: _____ | <input type="checkbox"/> Weight: _____ | <input type="checkbox"/> Progress Notes Attached |
|--|---|--|---|

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

***Approved by Pharmacy and Therapeutics Committee: 4/16/2015**

REVISED/UPDATED: 10/9/2015; 12/29/2015; 12/20/2016; 9/24/2017;